Irvine, Calif. (April 2, 2019) – Ocutrx Vision Technologies, LLC, an advanced research and development California-based manufacturer of augmented reality (AR) glasses, today announced the issuance of the company's second US patent, which will protect the company's unique eye tracking technology for patients with macular degeneration and other low vision conditions—cementing the company's place as a pioneer in both contact lens displays for AR and eye tracking technology for AR/XR applications.

"The new patent first covers using eye tracking as a part of the on-board Visual Field & Scotoma Edge Detection Self-Calibration mode," said Dr. Thomas A. Finley, M.D., head of the Tulsa Retina Consultants and chairman of the Ocutrx Medical Advisory Board, "This helps in fixing the analog eye defect alignment with the digital AR headset. The results of self-calibration are validated or invalidated based on verifying eye tracking and fixation, which is done concurrently while administering the eye tests. Also covered is eye tracking when displaying the Oculenz Computer Modified Image, which keeps the modified image aligned with the gaze of the patient."

The Oculenz patient user interface keeps the zoom, skew or other manipulation features aligned to improve visual acuity. Eye tracking permits a differential adjustment to account for the potential for differing defects in each eye.

The language in the second patent covers the general use of eye tracking with a head's-up display, noting, "another advantage" of the Oculenz heads-up display is that "this type of wide field-of-vision goggles or glasses can be used in conjunction with one or more cameras, which are typically head mounted and combined with proximity sensors, motion sensors, head and eye tracking, a feature which is advantageous for understanding a user's specific field of vision for adjustments, and to measure triangulated distance." stated Mitchael C. Freeman, COO of Ocutrx. "This makes our eye-tracking patents applicable across the board for AR/XR."

Ocutrx Founder and CEO Michael Freeman revealed that the patent teaches that eye tracking can be used to judge the convergence and divergence of an image projected onto the lens to account for the epipolar geometry change in the field of vision (FOV), which occurs when human eyes converge when looking at objects closely and diverge when looking far away in an effort to maintain single binocular vision. According to Freeman, "This feature is especially helpful in ultra-high definition 3D applications, medical or non-medical, where eye tracking sensors are used to automatically change the field of vision to each eye and the presentation of a 3D image to each retina—including creating a virtual zoom in/out method as the eyes look close or far away."

US Press Room Homepage